What is the P/E ratio of Nurexone Biologic 2024?
The Nurexone Biologic P/E ratio is -5.75.
3 years
5 years
10 years
Max
Gain insights into Nurexone Biologic, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nurexone Biologic from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nurexone Biologic’s net earnings, an ultimate measure of its financial health and profitability.
Observe the yearly bars to understand the annual performance and growth of Nurexone Biologic. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
The expected values for the forthcoming years offer investors a glimpse into Nurexone Biologic’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Leveraging the comparison between Revenue and EBIT helps in assessing Nurexone Biologic’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nurexone Biologic’s growth potential.
Date | Nurexone Biologic Revenue | Nurexone Biologic EBIT | Nurexone Biologic Net Income |
---|---|---|---|
2025e | 0 undefined | -4.89 M undefined | -3.99 M undefined |
2024e | 0 undefined | -4.89 M undefined | -3.99 M undefined |
2023 | 0 undefined | -3.66 M undefined | -3.64 M undefined |
2022 | 0 undefined | -5.54 M undefined | -8.17 M undefined |
2021 | 0 undefined | -130,000 undefined | -130,000 undefined |
2020 | 0 undefined | -60,000 undefined | -20,000 undefined |
2019 | 0 undefined | -90,000 undefined | -60,000 undefined |
2018 | 0 undefined | -110,000 undefined | -100,000 undefined |
2017 | 0 undefined | -460,000 undefined | -630,000 undefined |
2016 | 0 undefined | -30,000 undefined | -30,000 undefined |
2015 | 0 undefined | -50,000 undefined | -80,000 undefined |
2014 | 0 undefined | -70,000 undefined | -70,000 undefined |
2013 | 0 undefined | -30,000 undefined | -30,000 undefined |
2012 | 0 undefined | -60,000 undefined | -60,000 undefined |
Revenue | EBIT | Net Income | |
---|---|---|---|
2012 | 0 USD | -60,000 USD | -60,000 USD |
2013 | 0 USD | -30,000 USD | -30,000 USD |
2014 | 0 USD | -70,000 USD | -70,000 USD |
2015 | 0 USD | -50,000 USD | -80,000 USD |
2016 | 0 USD | -30,000 USD | -30,000 USD |
2017 | 0 USD | -460,000 USD | -630,000 USD |
2018 | 0 USD | -110,000 USD | -100,000 USD |
2019 | 0 USD | -90,000 USD | -60,000 USD |
2020 | 0 USD | -60,000 USD | -20,000 USD |
2021 | 0 USD | -130,000 USD | -130,000 USD |
2022 | 0 USD | -5.54 M USD | -8.17 M USD |
2023 | 0 USD | -3.66 M USD | -3.64 M USD |
2024e | 0 USD | -4.89 M USD | -3.99 M USD |
2025e | 0 USD | -4.89 M USD | -3.99 M USD |
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
- | - | - | - | - | - | - | - | - | - | - | - | - | - |
- | - | - | - | - | - | - | - | - | - | - | - | - | - |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5 | -3 | -4 | -4 |
- | - | - | - | - | - | - | - | - | - | - | - | - | - |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8 | -3 | -3 | -3 |
- | - | - | - | - | - | - | - | - | - | - | -62.50 | - | - |
0.4 | 0.5 | 0.46 | 0.4 | 0.44 | 2.06 | 2.38 | 2.47 | 2.54 | 2.54 | 37.73 | 44.72 | 0 | 0 |
- | - | - | - | - | - | - | - | - | - | - | - | - | - |
The Nurexone Biologic Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Nurexone Biologic is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
3 years
5 years
10 years
Max
The gross margin, expressed as a percentage, delineates the gross profit made from the Nurexone Biologic's sales revenue. A higher gross margin percentage indicates that the Nurexone Biologic retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT margin represents the Nurexone Biologic's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
The revenue margin demonstrates the Nurexone Biologic's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nurexone Biologic's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nurexone Biologic. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nurexone Biologic's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Nurexone Biologic Gross margin | Nurexone Biologic Profit margin | Nurexone Biologic EBIT margin | Nurexone Biologic Profit margin |
---|---|---|---|
2025e | 0 % | 0 % | 0 % |
2024e | 0 % | 0 % | 0 % |
2023 | 0 % | 0 % | 0 % |
2022 | 0 % | 0 % | 0 % |
2021 | 0 % | 0 % | 0 % |
2020 | 0 % | 0 % | 0 % |
2019 | 0 % | 0 % | 0 % |
2018 | 0 % | 0 % | 0 % |
2017 | 0 % | 0 % | 0 % |
2016 | 0 % | 0 % | 0 % |
2015 | 0 % | 0 % | 0 % |
2014 | 0 % | 0 % | 0 % |
2013 | 0 % | 0 % | 0 % |
2012 | 0 % | 0 % | 0 % |
Gross margin | EBIT margin | Profit margin | |
---|---|---|---|
2012 | 0 % | 0 % | 0 % |
2013 | 0 % | 0 % | 0 % |
2014 | 0 % | 0 % | 0 % |
2015 | 0 % | 0 % | 0 % |
2016 | 0 % | 0 % | 0 % |
2017 | 0 % | 0 % | 0 % |
2018 | 0 % | 0 % | 0 % |
2019 | 0 % | 0 % | 0 % |
2020 | 0 % | 0 % | 0 % |
2021 | 0 % | 0 % | 0 % |
2022 | 0 % | 0 % | 0 % |
2023 | 0 % | 0 % | 0 % |
2024e | 0 % | 0 % | 0 % |
2025e | 0 % | 0 % | 0 % |
3 years
5 years
10 years
Max
Revenue per share represents the total revenue Nurexone Biologic earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT per share indicates Nurexone Biologic's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income per share, or earnings per share (EPS), reveals the portion of Nurexone Biologic’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nurexone Biologic's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Date | Nurexone Biologic Sales per Share | Nurexone Biologic EBIT per share | Nurexone Biologic Earnings per Share |
---|---|---|---|
2025e | 0 undefined | 0 undefined | -0.08 undefined |
2024e | 0 undefined | 0 undefined | -0.08 undefined |
2023 | 0 undefined | -0.08 undefined | -0.08 undefined |
2022 | 0 undefined | -0.15 undefined | -0.22 undefined |
2021 | 0 undefined | -0.05 undefined | -0.05 undefined |
2020 | 0 undefined | -0.02 undefined | -0.01 undefined |
2019 | 0 undefined | -0.04 undefined | -0.02 undefined |
2018 | 0 undefined | -0.05 undefined | -0.04 undefined |
2017 | 0 undefined | -0.22 undefined | -0.31 undefined |
2016 | 0 undefined | -0.07 undefined | -0.07 undefined |
2015 | 0 undefined | -0.13 undefined | -0.2 undefined |
2014 | 0 undefined | -0.15 undefined | -0.15 undefined |
2013 | 0 undefined | -0.06 undefined | -0.06 undefined |
2012 | 0 undefined | -0.15 undefined | -0.15 undefined |
Sales per Share | EBIT per share | Earnings per Share | |
---|---|---|---|
2012 | 0 USD | -0.15 USD | -0.15 USD |
2013 | 0 USD | -0.06 USD | -0.06 USD |
2014 | 0 USD | -0.15 USD | -0.15 USD |
2015 | 0 USD | -0.13 USD | -0.2 USD |
2016 | 0 USD | -0.07 USD | -0.07 USD |
2017 | 0 USD | -0.22 USD | -0.31 USD |
2018 | 0 USD | -0.05 USD | -0.04 USD |
2019 | 0 USD | -0.04 USD | -0.02 USD |
2020 | 0 USD | -0.02 USD | -0.01 USD |
2021 | 0 USD | -0.05 USD | -0.05 USD |
2022 | 0 USD | -0.15 USD | -0.22 USD |
2023 | 0 USD | -0.08 USD | -0.08 USD |
2024e | 0 USD | 0 USD | -0.08 USD |
2025e | 0 USD | 0 USD | -0.08 USD |
3 years
5 years
10 years
Max
Revenue per share represents the total revenue Nurexone Biologic earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT per share indicates Nurexone Biologic's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income per share, or earnings per share (EPS), reveals the portion of Nurexone Biologic’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nurexone Biologic's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Number of stocks | |
---|---|
2012 | 400,000 Aktien |
2013 | 500,000 Aktien |
2014 | 460,000 Aktien |
2015 | 400,000 Aktien |
2016 | 440,000 Aktien |
2017 | 2.06 M Aktien |
2018 | 2.38 M Aktien |
2019 | 2.47 M Aktien |
2020 | 2.54 M Aktien |
2021 | 2.54 M Aktien |
2022 | 37.73 M Aktien |
2023 | 44.72 M Aktien |
2024e | 44.72 M Aktien |
2025e | 44.72 M Aktien |
Date | EPS Estimate | EPS Actual | Quarterly report |
---|---|---|---|
3/31/2024 | -0.02 | -0.02 (2.91 %) | 2024 Q1 |
12/31/2023 | -0.02 | -0.02 (27.18 %) | 2023 Q4 |
9/30/2023 | -0.02 | -0.03 (-26.21 %) | 2023 Q3 |
6/30/2023 | -0.02 | -0.02 (2.91 %) | 2023 Q2 |
% | Name | Stocks | Change | Date |
---|---|---|---|---|
6.67 % | Druker (Yoram) | 3,230,000 | 0 | 5/23/2023 |
1.40 % | Mayron (Ron) | 680,000 | 0 | 5/23/2023 |
0.14 % | Richardson (James A) | 70,000 | -135,000 | 5/23/2023 |
The Nurexone Biologic P/E ratio is -5.75.
The Nurexone Biologic P/S ratio is 0.
The AlleAktien quality score for Nurexone Biologic is 4/10.
The revenue cannot currently be calculated for Nurexone Biologic.
The expected Nurexone Biologic profit is -3.99 M USD.
No history available for Nurexone Biologic.
Nurexone Biologic pays a dividend of 0 USD distributed over payouts per year.
The dividend cannot currently be calculated for Nurexone Biologic or the company does not pay out a dividend.
The ISIN of Nurexone Biologic is CA67059R1091.
The WKN of Nurexone Biologic is A3DNSU.
The ticker of Nurexone Biologic is NRX.V.
Over the past 12 months, Nurexone Biologic paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nurexone Biologic is expected to pay a dividend of 0 USD.
The current dividend yield of Nurexone Biologic is .
Nurexone Biologic pays a quarterly dividend. This is distributed in the months of .
Nurexone Biologic paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Nurexone Biologic is assigned to the '-' sector.
To receive the latest dividend of Nurexone Biologic from 7/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/12/2024.
The last dividend was paid out on 7/12/2024.
In the year 2023, Nurexone Biologic distributed 0 USD as dividends.
The dividends of Nurexone Biologic are distributed in USD.
Nurexone Biologic Ticker | Nurexone Biologic FIGI |
---|---|
NRX:CN | BBG002CV5Z46 |
NRX:CV | BBG002CV5Z73 |
NRX:CJ | BBG002CV5ZC7 |
NRX:TV | BBG002CV5ZG3 |
NRX:TN | BBG002CV5ZK8 |
NRX:TG | BBG002CV5ZL7 |
NRX:TK | BBG002CV5ZM6 |
NRX:TW | BBG002CV5ZN5 |
NRX:DV | BBG003G8C6S1 |
NRX:DS | BBG004J9YY81 |
NRX:DG | BBG005XRLH56 |
NRX:QF | BBG0086KLMB7 |
NRX:QH | BBG0086KLMC6 |
NRX:DK | BBG00DVN4C23 |
J90:GR | BBG00H90W3N5 |
J90:GF | BBG00H90W3P3 |
J90:GS | BBG00H90W3S0 |
J90:GM | BBG00H90W3T9 |
ENER1EUR:XH | BBG00H9TZ7G8 |
ENER1EUR:XF | BBG00H9TZ7J5 |
ENER1EUR:XE | BBG00H9TZ7L2 |
ENER1EUR:XL | BBG00H9TZ7N0 |
ENER1EUR:XG | BBG00H9TZ7P8 |
ENER1EUR:XO | BBG00H9TZ7Q7 |
ENER1EUR:XA | BBG00H9TZ7W0 |
ENER1EUR:XT | BBG00H9TZ7Y8 |
ENER1EUR:XW | BBG00H9TZ7Z7 |
ENER1EUR:XU | BBG00H9TZ803 |
ENER1EUR:XV | BBG00H9TZ812 |
ENER1EUR:EU | BBG00H9TZ830 |
NRX:QG | BBG00LN9LX93 |
ENER1CAD:X2 | BBG00Y441QJ3 |
ENER1CAD:XH | BBG00Y441QL0 |
ENER1CAD:XF | BBG00Y441QN8 |
ENER1CAD:XE | BBG00Y441QQ5 |
ENER1CAD:XL | BBG00Y441QS3 |
ENER1CAD:XG | BBG00Y441QT2 |
ENER1CAD:XO | BBG00Y441QV9 |
ENER1CAD:XA | BBG00Y441QZ5 |
ENER1CAD:XT | BBG00Y441R10 |
ENER1CAD:XW | BBG00Y441R29 |
ENER1CAD:XU | BBG00Y441R38 |
ENER1CAD:XV | BBG00Y441R56 |
ENER1CAD:XM | BBG00Y441R65 |
ENER1CAD:X1 | BBG00Y441RC8 |
ENER1CAD:EU | BBG00Y441RF5 |
J90:LA | BBG018H9JCC3 |
J90:LU | BBG018J35D37 |
NRX:BF | BBG019LPKNV3 |
J90:TH | BBG019SQHK44 |
J90:GZ | BBG01BDC07V3 |
NRX:HD | BBG01J14RNR8 |
NRX:HX | BBG01J15GYP5 |
NRXBF:US | BBG01J1R61K5 |
NRXBF:PQ | BBG01J1R61Z9 |
NRXBF:UV | BBG01J1R6205 |
Our stock analysis for Nurexone Biologic Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nurexone Biologic Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.